MIAMI Program

post traumatic brain injuries

Olgram develops new molecules to cure the immune system deficiencies after traumatic brain injuries (TBI) that affects 5 million people worldwide every year.

The World Health Organization (WHO) estimates that traumatic brain injury is the third leading cause of death and disability in 2019 and its economic impact in the United States and Europe is estimated at $76.5 billion in direct and indirect costs.

A serious threat to health

TBI is a particularly serious threat to health in newborns, children, the military service personnel, and athletes and can result in persistent and debilitating impairments in cognition, sensory function, mental health, motor function and the proper functioning of the immune system.

Despite being a prevalent and pressing global medical issue, there are currently no FDA or EMA approved therapeutics to treat TBI related immune disorders.

Our process

Olgram is now conducting regulatory preclinical research with its lead candidate to save the life of millions of TBI patients.

A new biomarker

Olgram with Nantes University developed a rapid, cheap, easy to implement reliable biomarker to anticipate the onset of pneumonia on 168 patients with trauma.

The sensitivity and specificity are above 90% with this technique against 65% for the current CPIS (Clinical Pulmonary Infection Score) used routinely.

Our process

Samples from routinely endotracheal aspirations are processed and deposited on slides by cytospin, tools already widely used on hospital technical platforms. The slides can then be directly observed by microscopy and a software analyses different validated parameters to predict the onset of the disease.


We create a company that will save the life of many patients while creating a virtuous industrial process.

Learn more


We will be present at the following events, do not hesitate to contact us if you wish to meet.

Learn more